Cargando…
Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson’s disease
The development of disease-modifying drugs and differential diagnostic agents is an urgent medical need in Parkinson’s disease. Despite the complex pathophysiological pathway, the misfolding of alpha-synuclein has been identified as a putative biomarker for detecting the onset and progression of the...
Autores principales: | Nwabufo, Chukwunonso K., Aigbogun, Omozojie P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281355/ https://www.ncbi.nlm.nih.gov/pubmed/35831620 http://dx.doi.org/10.1007/s00415-022-11267-9 |
Ejemplares similares
-
Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
por: Menon, Sindhu, et al.
Publicado: (2022) -
Rationale for Therapeutic Silencing of Alpha-Synuclein in Parkinson’s Disease
por: Maraganore, Demetrius M.
Publicado: (2011) -
Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson’s Disease
por: König, Annekatrin, et al.
Publicado: (2018) -
Alpha-Synuclein Aggregation in Parkinson's Disease
por: Srinivasan, E., et al.
Publicado: (2021) -
Alpha-Synuclein and Cognitive Decline in Parkinson Disease
por: Fan, Tian-Sin, et al.
Publicado: (2021)